missing translation for 'onlineSavingsMsg'
Learn More

ML167, MedChemExpress

Product Code. 16499467
Encompass_Preferred
Click to view available options
Quantity:
5 mg
10 mg
25 mg
50 mg
Unit Size:
10mg
25mg
50mg
5mg
This item is not returnable. View return policy

Product Code. 16499467

Brand: Medchem Express HY15951

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

MedChemExpress ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC50 of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B.

ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC50 of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B.

Specifications

Chemical Name or Material ML167
CAS 1285702-20-6
Color Khaki
Purity Grade Notes Research
Molecular Formula C19H17N3O3
Quantity 5 mg
Synonym CID44968231 NCGC00188654
Solubility Information DMSO : 16.67 mg/mL (49.71 mM; Need ultrasonic)
SMILES OCC1=CC=C(C2=CC3=C(NCC4=CC=C(C)O4)N=CN=C3C=C2)O1
Molecular Weight (g/mol) 335.36
Formula Weight 335.36
Percent Purity 98.08%
Grade Research
Physical Form Solid
For Use With (Application) Cancer-Kinase/protease
Show More Show Less

Research purposes only

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.